Correction of SMN2 pre-mRNA splicing by antisense U7 small nuclear RNAs

被引:83
作者
Madocsai, C [1 ]
Lim, SR [1 ]
Geib, T [1 ]
Lam, BJ [1 ]
Hertel, KJ [1 ]
机构
[1] Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA
关键词
spinal muscular atrophy; SMN1 gene product; SMN2 gene product; RNA splicing; alternative splicing; U7; snRNA; gene therapy;
D O I
10.1016/j.ymthe.2005.08.022
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Mutations in one of the duplicated survival of motor neuron (SMN) genes lead to the progressive loss of motor neurons and subsequent development of spinal muscular atrophy (SMA), a common, and usually fatal, hereditary disease. Homozygous absence of the telomeric copy (SMN1) correlates with development of SMA because differential splicing of the centromeric copy (SMN2) leads to exon 7 skipping and predominantly produces a biologically inactive protein isoform. To increase exon 7 inclusion of SMN2, we have designed a series of vectors that express modified U7 snRNAs containing antisense sequences complementary to the 3' splice site of SMN exon 8. Over 20 anti-SMN U7 snRNAs were tested for their ability to promote exon 7 inclusion in the SMN2 gene. Transient expression of anti-SMN U7 snRNAs in HeLa cells modulated SMN2 splicing to -70% exon 7 inclusion in a sequence-specific and dose-dependent manner. Significantly, the administration of anti-SMN U7 snRNPs results in an increase in the concentration of SMN protein. These results suggest that modulation of SMN2 pre-mRNA splicing by modified U7 snRNAs; provides a promising form of gene therapy for the treatment of SMA.
引用
收藏
页码:1013 / 1022
页数:10
相关论文
共 48 条
[1]   Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients [J].
Andreassi, C ;
Jarecki, J ;
Zhou, JH ;
Coovert, DD ;
Monani, UR ;
Chen, XC ;
Whitney, M ;
Pollok, B ;
Zhang, ML ;
Androphy, E ;
Burghes, AHM .
HUMAN MOLECULAR GENETICS, 2001, 10 (24) :2841-2849
[2]   Identification and characterization of Gemin7, a novel component of the survival of motor neuron complex [J].
Baccon, J ;
Pellizzoni, L ;
Rappsilber, J ;
Mann, M ;
Dreyfuss, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :31957-31962
[3]   Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases [J].
Blencowe, BJ .
TRENDS IN BIOCHEMICAL SCIENCES, 2000, 25 (03) :106-110
[4]   Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy [J].
Brichta, L ;
Hofmann, Y ;
Hahnen, E ;
Siebzehnrubl, FA ;
Raschke, H ;
Blumcke, I ;
Eyupoglu, IY ;
Wirth, B .
HUMAN MOLECULAR GENETICS, 2003, 12 (19) :2481-2489
[5]   Structure and organization of the human survival motor neurone (SMN) gene [J].
Burglen, L ;
Lefebvre, S ;
Clermont, O ;
Burlet, P ;
Viollet, L ;
Cruaud, C ;
Munnich, A ;
Melki, J .
GENOMICS, 1996, 32 (03) :479-482
[6]   Correction of disease-associated exon skipping by synthetic exon-specific activators [J].
Cartegni, L ;
Krainer, AR .
NATURE STRUCTURAL BIOLOGY, 2003, 10 (02) :120-125
[7]   Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 [J].
Cartegni, L ;
Krainer, AR .
NATURE GENETICS, 2002, 30 (04) :377-384
[8]   Treatment of spinal muscular atrophy by sodium butyrate [J].
Chang, JG ;
Hsieh-Li, HM ;
Jong, YJ ;
Wang, NM ;
Tsai, CH ;
Li, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) :9808-9813
[9]  
COBBEN JM, 1995, AM J HUM GENET, V57, P805
[10]   Formation of the 3′ end of histone mRNA [J].
Dominski, Z ;
Marzluff, WF .
GENE, 1999, 239 (01) :1-14